Lung Protocol

1. Summary

Ranks

Liquidity

-

Developer

-

Social

52

Momentum (beta)

0

Stack Rank™

-

Price

$0.000010520000 0.0%

Market Cap

$0.00 (#10716)

Supply

/

Tags

Number Ethereum Ecosystem

More Metrics

Price
52W High price	$0.000390716400
52W High date	21st Feb 2022 (3 years ago)
All Time High (ATH) Date	4th Jan 2025 (1 month ago)
All Time Low (ATL) Date	4th Jan 2025 (1 month ago)

Supply & Trading Volume

Less Metrics

Description

Lung-MAP: A Groundbreaking Clinical Trial for Lung Cancer

Read More

Lung-MAP: A Groundbreaking Clinical Trial for Lung Cancer

The Lung Master Protocol (Lung-MAP) is a historic clinical trial aimed at developing targeted therapies for squamous cell carcinoma (SCC) and non-small cell lung cancer (NSCLC). This innovative approach uses a multi-drug, multi-sub-study, biomarker-driven model to match patients with the most suitable treatments based on their unique genetic profiles.

How it Works

1. Comprehensive Screening: Patients undergo genomic sequencing to identify actionable molecular abnormalities in their tumors.
2. Assignment to Sub-Studies: Patients are matched to specific treatment arms based on the detected biomarkers.
3. Targeted Therapies: Investigational treatments are tested, along with standard of care, to assess effectiveness.

Collaborative Efforts

Lung-MAP involves an unprecedented public-private partnership among organizations, including:

• National Cancer Institute (NCI)
• National Institutes of Health (NIH)
• U.S. Food and Drug Administration (FDA)
• Pharmaceutical companies
• Research institutions
• Patient advocacy groups

Goals and Outcomes

1. Efficient Development: Streamline the development process by reducing the time and resources needed to bring new treatments to market.
2. Personalized Medicine: Match patients with the most effective treatments based on their genetic profiles.
3. Improved Patient Care: Enhance access to promising drugs and improve treatment outcomes for patients with advanced lung cancer.

Benefits and Impact

• Streamlined Clinical Trials: Reduce costs, time, and infrastructure needed for trials.
• Increased Patient Access: Expand opportunities for patients to participate in clinical trials.
• Advancements in Precision Medicine: Drive the development of targeted therapies for lung cancer and other diseases.

Participating Sites and Eligibility

Lung-MAP operates at over 700 sites across the United States, offering a revolutionary approach to clinical trials and treatment for advanced lung cancer patients.

Show Less